Anxiety • Reunion

Now Enrolling
Written By Kirsten Hirst

RE-104-203-GAD

About the Study

The purpose of this study is to determine if treatment with a single dose of RE104 reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.

This study is sponsored by Reunion

Eligibility

You may be eligible to participate in this study if you:

  • are between the ages of 18-74 years old

  • on stable use of antidepressants (i.e., SSRIs or SNRIs) or psychotherapy, or is willing to delay the use until the end of study

  • have been diagnosed with Generalized Anxiety Disorder (GAD)

  • are willing and able to comply with the conditions and requirements of the study

Apply Today

If you are interested in participating in this clinical trial, please call our friendly staff at 801-871-5516 today. You can also fill out the contact form below.

 
Kirsten Hirst
Next

Depression • MindMed